



## Defining Asthma: Clinical Criteria




From: Woolcock, AJ. "Asthma" in *Textbook of Respiratory Medicine*, 2nd ed. Murray, Nadel, eds. (Saunders:Philadelphia) pp. 1288-1330, 1994

## Defining Asthma: Bronchial Hyperresponsiveness



## Impaired Ventilation in Asthma




Normal




Asthmatic

From: Klarreich, *Nature* 424:873, 2003

## Dynamic Imaging of Asthma




Pre-treatment



Post-treatment

## Mucus Plugging is a Prominent Feature of Moderate to Severe Asthma




From: Bousquet et al., *Am. J. Respir. Crit. Care Med.*, 161:1720, 2000

## Some Landmarks in the History of the Immunology of Asthma\*

- 1989: Early genetic mapping assigns chromosome 5q to the “cytokine gene cluster”
- Early 1990s: Asthma is an inflammatory disease
- 1990: Upregulation of ICAM-1 and LFA-1, adhesion molecules, in a primate model of asthma
- 1992:  $T_H2$  bias of lymphocytes in asthma
- 1997: Experimental support grows for the “Hygiene hypothesis,” first proposed in 1989
- 2000: Role of Tregs in regulation of asthma


\*Highly biased view; therefore, commit to memory

## Nature of Inflammatory Cells in Biopsies From Airways of Asthmatics



From: Ollerenshaw and Woolcock., *Am. Rev. Resp. Dis.* 145:922, 1992

## Defining Asthma: Pathological Features




From: Bousquet et al., *Am. J. Respir. Crit. Care Med.*, 161:1720, 2000

## Fibrin Deposition in the Airways of Asthmatics


Human

Mouse




From: Wagers et al. *J. Clin. Invest.* 114:104-111, 2004

## Tissue "Compartments" in Asthma



## Adhesion Molecules ICAM-1 and LFA-1 in Experimental Asthma




From: Wegner et al., *Science* 247:456, 1990

## Asthma and the Immune Response



## Eosinophils and Asthma




From: Wills-Karp and Karp, *Science* 305:1726-1729, 2004

Asthma as a T<sub>H</sub>2-dominated Disease




## STAT-6 Signaling Pathways Leading to the Asthmatic Phenotype




From: Elias et al., *J. Clin. Invest.* 111:291, 2003

## Potential Drug Targets in Asthma



From: Barnes, *Nature Reviews Drug Discovery* 3:831, 2004

## Understanding the Immunology of Asthma Leads to Insights Into Novel Therapeutics



From: Barnes, *Nature Reviews Drug Discovery* 3:831,2004

## Who Gets Asthma?

4. M. Ishii et al., *J. Clin. Invest.* 101, 481 (1998); E. Weller et al., *Proc. Natl. Acad. Sci. U.S.A.* 95, 7324 (1998).

5. C. P. Fung and C. P. Phelan, *Respir. Dis.* 10, 102 (1985).

6. H. K. Kimura, T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

7. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

8. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

9. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

10. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

11. A. Oishi et al., *Cell* 88, 1037 (1996).

12. J. S. Srinivasan et al., *Am. J. Respir. Crit. Care Med.* 153, 1022 (1996).

13. A primary genetic locus, 9p24, encodes a protein that is essential for the development of the immune system and for the development of the immune system. The protein is essential for the development of the immune system and for the development of the immune system. The protein is essential for the development of the immune system and for the development of the immune system.

14. Possible B cell synthesis was described (10). Individual B cell clones were examined and 100% of the B cell clones in the peripheral blood and in the spleen were found to be of the same clone. The results indicate that the B cell clones in the peripheral blood and in the spleen were of the same clone. The results indicate that the B cell clones in the peripheral blood and in the spleen were of the same clone.

15. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

16. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

17. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

18. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

19. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

20. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

21. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

22. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

23. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

24. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

25. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

26. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

27. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

28. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

29. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

30. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

31. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

32. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

33. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

34. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

35. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

36. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

37. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

38. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

39. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

40. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

41. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

42. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

43. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

44. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

45. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

46. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

47. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

48. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

49. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

50. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

51. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

52. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

53. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

54. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

55. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

56. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

57. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

58. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

59. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

60. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

61. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

62. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

63. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

64. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

65. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

66. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

67. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

68. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

69. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

70. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

71. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

72. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

73. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

74. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

75. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

76. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

77. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

78. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

79. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

80. T. I. Gotoh, M. K. Shimizu, F. H. S. Wong, *Respir. Dis.* 10, 102 (1985).

## The Inverse Association Between Tuberculin Responses and Atopic Disorder

Taro Shirakawa, Tadano Enomoto, Shin-ichiro Shimazu, Julian M. Hopkin\*


Human immune responses are heterogeneous and may involve antagonism between T helper (T<sub>H</sub>) lymphocyte subsets and their cytokines. Atopy is characterized by immediate hypersensitivity (IgE)-mediated hypersensitivity to agents such as dust mites and pollen, and it underlies the increasingly prevalent disorder asthma. Among Japanese schoolchildren, there was an strong inverse association between delayed hypersensitivity to *Mycobacterium tuberculosis* and atopy. Positive tuberculin responses predicted a lower incidence of asthma, lower serum IgE levels, and cytokine profiles biased toward T<sub>H</sub>1 type. Exposure and response to *M. tuberculosis* may, by modification of immune profiles, inhibit atopic disorder.

Atopy is a state of allergic response, mediated by IgE, to largely innocuous, common environmental antigens (allergens) such as those derived from house dust mites and plant pollen (1). It underlies the clinical diseases of asthma, hay fever, and eczema (2). Atopy can be recognized by allergen-specific IgE in serum or by immediate-type hypersensitivity reactions to allergen upon intradermal skin testing. Heterogeneous genetic and environmental factors interact in the development of atopy (3), a set of cytokines—interleukin-4 (IL-4), IL-10, and IL-13—derived from the T<sub>H</sub>2 subset of T lymphocytes—is central to mediating IgE production and the development of immediate hypersensitivity (4).

In recent decades there has been an increase in severity, and probably in prevalence, of atopic disorders in developed countries (5). Studies on migrants from developing to developed countries support the importance of ecological environmental changes associated with "Westernization" (6). The nature of these environmental changes is unclear, but speculation has focused on increased air pollution or other toxics in the environment, increased indoor exposure to dust mite antigens in less ventilated modern homes, and dietary changes (7). One factor temporally associated with the rise of atopy is the decline of many infectious diseases in developed countries as the result of improved living standards and immunization programs (8). Data on the risk of atopy

in children of parents with atopy are consistent with the hypothesis that atopy is a state of immune deficiency. In the case of tuberculosis, an important marker of T<sub>H</sub>1-mediated acquired immunity (see synopsis with protection) is the development of delayed-type hypersensitivity. This can be tested by observing the reaction, after 48 hours, to the intradermal injection of tuberculin protein (12). There is likely a "cage" relation between the degree of delayed hypersensitivity and the risk of atopy (13).

To test for clinical evidence of antagonism between delayed hypersensitivity to tuberculin and immediate atopic responses, we conducted an epidemiologic survey in a county of the Wakayama prefecture in southern Honshu, Japan, where there has been a long-established program of tuberculosis testing and immunization with attenuated bovine *M. tuberculosis* vaccine Bacillus Calmette-Guérin (BCG) after birth and at 6 and 12 years of age (14). From a population of approximately 1000 12- to 13-year-old schoolchildren attending the 18 junior high schools of the county in 1995, we studied 867 children with complete retrospective records of their tuberculin responses. We administered a



**Fig. 1.** Delayed hypersensitivity to tuberculin (DHT, in millimeters) and relation to serum IgE. (A) Histogram showing bimodal distribution of responses to tuberculin, assayed as DHT at 12 years of age in 867 Japanese schoolchildren. (B) Plot of log(total serum IgE) versus DHT in the same children ( $r = -0.492$ ,  $P < 0.001$ ).

From: Shirakawa et al., *Science* 275:77, 1997

**Table 1.** History of infectious diseases, atopic symptoms, IgE levels, and cytokine profiles in subjects grouped by tuberculin reactivity. ASE, allergen-specific IgE; UD, undetectable.

Measurement	Group 1 (n = 290)	Group 2 (n = 289)	Group 3 (n = 213)	Group 4 (n = 75)	Total (n = 867)
<b>Tuberculin response</b>					
At 6 years	-	-	+	+	
At 12 years	-	+	+	-	
<b>Positive antiviral immunity (%)</b>					
Measles (history + vaccine)	83.4	87.2	84.5	81.3	84.3
Chicken pox (history + vaccine)	86.9	82.3	82.2	82.7	83.9
Mumps (history + vaccine)	62.8	60.9	60.1	57.3	61.0
Number with IgE to Ascaris	2	2	2	1	7
<b>Symptoms (%)</b>					
Atopy (past + present)	46.8	33.9 <sup>††</sup>	25.8 <sup>††</sup>	38.7	36.6
Atopy (present)	32.1	7.9 <sup>†††</sup>	9.8 <sup>†††</sup>	30.7	18.5
Asthma (past + present)	13.4	4.1 <sup>††</sup>	3.7 <sup>††</sup>	6.8	7.4
Rhinitis (past + present)	16.2	4.8 <sup>††</sup>	8.6 <sup>†</sup>	14.6	10.4
Eczema (past + present)	22.7	12.8 <sup>††</sup>	12.2 <sup>††</sup>	16.0	16.2
Geometric mean IgE (IU/ml)	208	149 <sup>**</sup>	98 <sup>**</sup>	178	154
Positive ASE (%)	55.8	43.9 <sup>††</sup>	41.8 <sup>††</sup>	53.3	48.2
Atopic (high IgE or positive ASE) (%)	65.5	54.0 <sup>††</sup>	49.2 <sup>††</sup>	61.3	57.3
<b>Median cytokine level (pg/ml)</b>					
IL-4	1.88	0.96 <sup>†</sup>	0.92 <sup>†</sup>	1.66	1.22 (10.2-UD) <sup>§</sup>
IL-13	18.3	10.2 <sup>†††</sup>	7.8 <sup>†††</sup>	19.1	14.2 (45.6-UD)
IL-10	5.9	3.1 <sup>††</sup>	2.9 <sup>††</sup>	5.9	3.9 (10.2-UD)
IL-12	UD	UD	UD	UD	UD
IFN- $\gamma$	7.8	11.0 <sup>††</sup>	13.2 <sup>††</sup>	6.4	10.5 (23.2-UD)
Positive family history within three generations (%)	54.1	49.8	49.8	48.0	51.0
Mean BMI	21.1	22.0	21.9	21.2	21.6

<sup>\*\*</sup>P < 0.01, <sup>\*\*\*</sup>P < 0.001 on the basis of Student's test. <sup>†</sup>P < 0.05, <sup>††</sup>P < 0.01, <sup>†††</sup>P < 0.001 on the basis of a median test. <sup>‡</sup>P < 0.05, <sup>‡†</sup>P < 0.01, <sup>‡††</sup>P < 0.001 on the basis of  $\chi^2$  against group 1, respectively. <sup>§</sup>Maximum-minimum values.

From: Shirakawa et al., *Science* 275:77, 1997


**Table 2.** Odds ratios for atopy and for occurrence and remission of atopic symptoms in positive versus negative tuberculin responders by age. Multiple logistic analysis was conducted with the SPSSX package, version 2.2. In all models, allowance was made for dichotomized variables including sex, life-style, nutritional status, environmental factors, and family history. Only significant values are shown.

Tuberculin response	Odds ratio		
	Atopy	Atopic symptoms	
		Occurrence	Remission
Conversion to positive up to 6 years of age	0.50 (0.29 to 0.83) <sup>*</sup>	Asthma: 0.31 (0.22 to 0.45) <sup>*</sup> Eczema: 0.50 (0.33 to 0.91) <sup>*</sup>	Asthma: 8.2 (6.0 to 9.8) <sup>**</sup> Eczema: 1.6 (1.0 to 2.2) <sup>*</sup>
Conversion to positive between 6 and 12 years of age	0.43 (0.25 to 0.83) <sup>**</sup>	Asthma: 0.42 (0.24 to 0.56) <sup>*</sup>	Asthma: 6.0 (2.8 to 10.3) <sup>***</sup> Eczema: 6.7 (4.8 to 11.4) <sup>***</sup> Rhinitis: 9.0 (6.2 to 14.2) <sup>***</sup>

<sup>\*</sup>P < 0.05, <sup>\*\*</sup>P < 0.01, <sup>\*\*\*</sup>P < 0.005.

From: Shirakawa et al., *Science* 275:77, 1997

# Environmental Influences and Asthma: The Hygiene Hypothesis



## Asthma, rhinitis, other respiratory diseases

### Hay fever and asthma in relation to markers of infection in the United States

Paolo Maria Matricardi, MD,<sup>a</sup> Francesco Rosmini, DSc,<sup>b</sup> Valentina Panetta, DSc,<sup>a</sup> Luigina Ferrigno, BSc,<sup>a</sup> and Sergio Bonini, MD<sup>a</sup> Rome, Italy

**Background:** The hygiene hypothesis proposes that declining exposure to infections is implicated in the rising trend of allergy and asthma.

**Objective:** We sought to test this hypothesis by examining the relationship of hay fever, asthma, and atopic sensitization with markers of infection in a large general population sample of the United States.

**Methods:** We analyzed the data of 33,994 US residents recorded in a public database of a nationally representative cross-sectional survey (Third National Health and Nutrition Examination Survey, 1988-1994). The variables examined were sociodemographic information, lifetime diagnosis and age at first diagnosis of hay fever or asthma, current skin sensitization to 9 airborne allergens and peanut, and current serology for *Toxoplasma gondii*, herpes simplex viruses type 1 and 2, and hepatitis A, B, and C viruses.

**Results:** Hay fever (adjusted odds ratio, 0.27; 95% CI, 0.18-0.41;  $P < .001$ ) and asthma (adjusted odds ratio, 0.42; 95% CI, 0.21-0.86;  $P < .001$ ) were less frequent in subjects seropositive for hepatitis A virus (HAV), *T. gondii*, and herpes simplex virus 1 versus seronegative subjects after adjusting for age, sex, race, urban residence, census region, family size, income, and education. Skin sensitization to peanut and to all the airborne allergens examined, except for cockroach, was less frequent among HAV-seropositive versus HAV-seronegative subjects younger than 40 years of age. The prevalence of hay fever and asthma diagnosed at or before 18 years of age in HAV-seropositive subjects increased progressively from 2.7% (95% CI, 0.7%-4.7%) and 0.2% (95% CI, 0.1%-1.6%), respectively, in cohorts born before 1928 to 8.5% (95% CI, 7.3%-9.7%) and 2.4% (95% CI, 1.8%-3.4%), respectively, in cohorts born in the 1960s, whereas they remained constant at around 2% in all cohorts of HAV-seronegative subjects.

**Conclusion:** In the United States serologic evidence of acquisition of certain infections, mainly food-borne and orofecal infections, is associated with a lower probability of having hay fever and asthma. Third National Health and Nutrition Examination Survey data support the hypothesis that hygiene is a major factor contributing to the increase in hay fever, asthma, and atopic sensitization in westernized countries. (J Allergy Clin Immunol 2002;110:381-7.)

From the Institute of Neurobiology and Molecular Medicine, Consiglio Nazionale delle Ricerche, and the Laboratory of Epidemiology and Biostatistics, Istituto Superiore di Sanità, Rome.

Received for publication March 20, 2002; revised May 8, 2002; accepted for publication May 21, 2002.

Reprint requests (present address): Paolo M. Matricardi, MD, WHO, World Health Organization, Chronic Respiratory Diseases and Allergies Unit, 20 Avenue Appia, CH-1211 Geneva 27, Switzerland.

© 2002 Mosby, Inc. All rights reserved.  
0895-0963/02/\$30.00 + 0 18152566/02  
doi:10.1053/j.ajci.2002.126368

**Key words:** Asthma, hay fever, hepatitis A virus, hygiene, infection, epidemiology, National Health and Nutrition Examination Survey III

Allergic diseases are spreading among populations living a Western lifestyle.<sup>1</sup> This epidemic has been variously attributed to pollution,<sup>2</sup> changes of diet,<sup>3</sup> and allergen exposure.<sup>4</sup> Another theory assumes that hygiene, by reducing exposure to infections, facilitates atopic responses and their inflammatory consequences at mucosa and skin surfaces, namely allergic asthma, rhinitis, and atopic eczema (the hygiene hypothesis).<sup>5,7</sup>

In Europe atopy was found to be less frequent in children raised in large<sup>8,9</sup> and poor families,<sup>9,10</sup> on farms,<sup>10</sup> or in communities living a traditional-type lifestyle<sup>11</sup> and in children attending daycare centers.<sup>12</sup> Moreover, allergic rhinitis and asthma were inversely associated to positive serology for hepatitis A virus (HAV)<sup>13,14</sup> and for *Toxoplasma gondii*,<sup>15</sup> suggesting that the level of exposure to orofecal and food-borne infections might influence the inception of respiratory allergic diseases.

The emergence of allergic asthma in unsanitary inner-city areas in the United States seems irreconcilable with the hygiene hypothesis.<sup>16,17</sup> However, longitudinal studies in Tucson, Ariz, provided the formal demonstration that early exposure to other children in the family or at a daycare center protects children from asthma and atopy, and this was attributed to an earlier and more frequent acquisition of infections.<sup>18</sup> Should this interpretation be correct, markers of exposure to a higher microbial burden, such as positive serology to HAV and *T. gondii*, should be independently associated with less allergy and asthma in the United States, as they are in Europe.

The Third National Health and Nutrition Examination Survey, 1988-1994 (NHANES III), examined a large national sample of Americans who responded to questionnaires on allergic and respiratory diseases and who underwent allergy skin testing and blood testing for markers of infections.<sup>19</sup> This public database provided a unique opportunity to investigate whether hay fever and asthma are indeed correlated with serology for HAV, *T. gondii*, and other markers of infection in the US general population.


#### METHODS

##### Study design

We examined a public registry of 33,994 US residents aged 1 to 90 years or older that includes clinical and laboratory data from NHANES III and analyzed the following variables: age, sex, race,

Asthma, rhinitis, other respiratory diseases


## Paradox: Why Does Chronic Infection with Helminths Not Predispose to Allergy?



From: Yazdanbakhsh et al., *Science* 296:490, 2002


## An Alternative to the Hygiene Hypothesis: Regulatory T-cells

## The Role of Regulatory T-cells in Modifying T<sub>H</sub>2 Immunity



Modified from: Maizels & Yazdanbakhsh, *Nature Rev. Immunol.* 3:733, 2003


## Immunotherapy of Atopic Diseases: a Role for Tregs?



Following 2-year grass pollen immunotherapy (closed circles), there were significant increases in (A) allergen-stimulated PBMC production of IL-10; (B) serum concentrations of grass pollen allergen-specific IgG4; and (C) serum inhibitory activity for allergen-IgE binding to B cells compared with controls (open circles). These changes were accompanied by a reduction in symptoms and inhibition allergen-induced late cutaneous response.

From: Robinson et al., *J. Clin. Invest* 114:1389, 2004


## Regulatory T-cells (Tregs) in Asthma



From: Robinson et al., *J. Clin. Invest* 114:1389, 2004



## Chemokines: the Gatekeepers of Inflammation

## Chemokines Direct Traffic




From: Luster, *Curr. Opin. Immunol.* 14:129, 2002

## Chemokine Receptor Specificity in $T_H2$ Cells and Eosinophils




## Potential Drug Targets in Asthma: Chemokines and their Receptors



From: Barnes, *Nature Reviews Drug Discovery* 3:831,2004


## Inflammatory Mediators as Novel Drug Targets

## Lipid Mediators in Asthma: LTB<sub>4</sub>, PGD<sub>2</sub>, LTC<sub>4</sub>



From: Luster and Tager *Nature Reviews Immunol.* 4:711, 2004


## Biological Activities of LTB<sub>4</sub> and PGD<sub>2</sub>



From: Tilley and Boucher *J. Clin. Invest.* 115:13-16 (2005)

## Adenosine Receptors as Drug Targets in Asthma

### Pro- and Anti-inflammatory Activities of Adenosine in Asthma



From: Tilley and Boucher  
*J. Clin. Invest.* 115:13-16 (2005)

## Summary of Genes Associated With Atopy

Gene	Chromosome	Phenotype	Genetic variation	Association	Reference
IL10	1q31	Total IgE, eosinophilia	Haplotypes	Yes	[23]
CHRM3	1q41	Atopy (cockroach)	Haplotype	Yes	[24]
IL1A	2q14	Atopy	4845G/T	Yes	[25]
CTLA4	2q33	Asthma severity	-318C/T	Yes	[26]
		BHR, asthma	-1147C/T	Yes	[27]
IL4	5q31	AD	-590C/T	Yes	[28]
IL13	5q31	Atopy	Haplotype	Yes	[29]
IL13	5q31	Atopy	Arg130Gln	Yes	[30]
		AD	Arg130Gln	Yes	[31]
CD14	5q21	Atopy, asthma, BHR, IgE, AD, Allergic Rhinitis	-159C/T	No	[32]
UGRP1	5q31-34	Asthma	-112G/A	Yes	[33]
B2AR	5q33-34		Arg16Gly	Yes	[34]
LTC4	5q33	Asthma	-444 (A/C)	No	[35]
		FEV <sub>1</sub> %		Yes	
IL12B	5q33-34	Asthma severity	-4475ns	Yes	[36]
		AD	1188A/C	Yes	[37]
MHC	6p21	Asthma, total IgE	DRB1	Yes	[38]
		Atopy	DRB1, DQ	Yes	[39]
		Total, specific IgE	DRB1	Yes	[40]
		Atopy, specific IgE	DRB1	Yes	[41]
		Allergic asthma	DRB1	Yes	[42]
		Asthma	DRB1	Yes	[43]
TNF	6p21	Allergic asthma	-308G/A	No	[42]
		Allergic asthma	-308G/A	Yes	[43]
		Allergic asthma	-308G/A	No	[44]
		Childhood asthma	-308G/A	No	[45]
		Asthma	-857C/T	Yes	[46]
		Asthma, IgE		No	[47]
TCRG	7p14	Asthma	1265A/G	Yes	[48]
Eotaxin 2	7q11.23	Asthma	STR(intron 4)	Yes	[49]
NOS3	7q36	Total IgE		Yes	[49]
NAT2	8p22	Allergic asthma	Slow acetylating allele	Yes	[50]
CC16	11q12	BHR	38A/C	Yes	[51]
		Asthma	38A/G	No	[52]
FCER1B	11q13	BHR	RsaIex7	Yes	[53]
		Asthma			
		Atopy			
GSTP1	11q13	FVC, FEV <sub>1</sub>	Ile103Val	Yes	[54]
SART-1	11q12-13	Atopy	774C/T	Yes	[55]
STAT6	12q13	Allergy	Gly485Ala	No	[56]
			2964C/A	No	[56]
			ICAM1 intron 1	Yes	
			haplotype	Yes	
IFNG	12q21	Total IgE	ICAM1 Intron 1	Yes	[57]
IFN11	13q14	Total IgE	Haplotype	Yes	[58]
IL4RA	16p12	Allergic asthma	Ile50Val	No	[58]
IL21R		Total IgE		Yes	[59]
CARD15	16q12	Allergic rhinitis	2104C/T	Yes	[60]
		Allergic rhinitis, AD	2722G/C	Yes	
		Atopy, total IgE	3020nsC	Yes	
		Asthma (late onset)	-282C/G	Yes	[61]
RANTES	17q21	Asthma severity	-282C/G	Yes	[62]
Eotaxin-1	17q21	Total IgE	Ala23Thr	Yes	[48]
		Total IgE in AD	-426C/T	Yes	[63]
ADAM 33	20p13	Asthma	Haplotype	Yes	[64]

From: Halapi and Hakonarson, *Curr. Opin. Pulm. Med.* 10:22, 2003

BHR, bronchial hyperresponsiveness; AD, atopic dermatitis; FVC, forced vital capacity; FEV<sub>1</sub>, forced expiratory volume in 1 second.